Product Attributes CAS # : 49557-75-7 Molecular Formula : C14H24N6O4Cu Sequence (AA) : C14H24N6O4 (free peptide), C14H22CuN6O4 (copper complex) Molecular Weight : 340.38 g/mol (peptide), 403.92 g/mol (copper complex) PubChem CID : 71587328 Half-Life : ~1-2 hours Synonyms : Copper Tripeptide-1, Cu-GHK, GHK-Cu Complex, Tripeptide-Copper, Prezatide, Kollaren, Glycyl-Histidyl-Lysine Type : Naturally occurring peptide-metal complex Research Focus : Beauty & Skin, Anti-Aging, Regeneration, Hair Growth Scientific References Expression of glycosaminoglycans and small proteoglycans in wounds: modulation by the tripeptide-copper complex glycyl-L-histidyl-L-lysine-Cu2+ Animal The human tripeptide GHK-Cu in prevention of oxidative stress and inflammatory conditions Review Regenerative and protective actions of the GHK-Cu peptide in the light of the new gene data Review The potential of GHK as an anti-aging peptide Review GHK peptide as a natural modulator of multiple cellular pathways in skin regeneration Review Thermodynamically stable ionic liquid microemulsions pioneer pathways for topical delivery and peptide retention In vitro Exploring the beneficial effects of GHK-Cu on an experimental model of DSS-induced ulcerative colitis in mice Animal The human tri-peptide GHK and tissue remodeling Review The tripeptide-copper complex glycyl-L-histidyl-L-lysine-Cu2+ stimulates matrix metalloproteinase-2 expression by fibroblast cultures In vitro In vivo stimulation of connective tissue accumulation by the tripeptide-copper complex glycyl-L-histidyl-L-lysine-Cu2+ in rat experimental wounds Animal Included In The Box Every product arrives in a premium, custom-designed PEPTIDE.Power box , engineered for convenience, hygiene, and safe storage in your refrigerator
If you have questions about which medication will work best for your specific symptoms and needs, connect with your administrator
251 Pharmacological DNMT inhibitors such as azacitidine and decitabine have shown the ability to induce differentiation and reduce stemness in CSC populations, especially in hematological malignancies
No.: 12621999000086 | Marketed FSSAI Lic
Bottom panel: 8-Isoprostane levels were reduced by 35% in the low dose group (gray bar) at week 2
NAC dose was titrated from 1200 mg per day to 3000 mg per day, and duration of the trial was 12 weeks
